[Medical methods for pregnancy termination. A review of literature and its potential role in Mexico and Latin America].
In this document, we review the relevant aspects of the different medical methods of abortion. We describe the principal medical regimens currently used in North America, Europe, and a growing number of developing countries. We also describe specific treatment regimens (which usually involve a combination of two drugs), physiological methods of action, potential side effects and complications, method requirements, including follow-up visits, any existing contraindication, and acceptability of these methods among patients. Finally, we comment on the potential role of medical abortion in Mexico and throughout Latin America.
Espinoza
Henry
H
Population Council, Oficina Regional para América Latina y el Caribe, Escondida 110, Col. Villa Coyoacán, 04000 México, D. F. hespinoza@popcouncil.org.mx
Ellertson
Charlote
C
García
Sandy
S
Schiavon
Raffaela
R
Langer
Ana
A
D000020:Abortifacient Agents, Nonsteroidal / Q000494:pharmacology; D000021:Abortifacient Agents, Steroidal / Q000009:adverse effects / Q000494:pharmacology; D000028:Abortion, Induced / Q000379:methods* / Q000639:trends; D001943:Breast Neoplasms / Q000188:drug therapy; D002986:Clinical Trials as Topic; D000075202:Contraindications; D004347:Drug Interactions; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007843:Latin America; D008727:Methotrexate / Q000494:pharmacology; D008800:Mexico; D015735:Mifepristone / Q000009:adverse effects / Q000494:pharmacology; D016595:Misoprostol / Q000494:pharmacology; D009130:Muscle, Smooth / Q000187:drug effects; D010342:Patient Acceptance of Health Care; D010353:Patient Education as Topic / Q000379:methods; D011247:Pregnancy; D011248:Pregnancy Complications / Q000209:etiology; D011372:Progestins / Q000037:antagonists & inhibitors / Q000502:physiology; D011453:Prostaglandins / Q000737:chemistry / Q000494:pharmacology; D011980:Receptors, Progesterone / Q000187:drug effects; D013762:Tetrahydrofolate Dehydrogenase / Q000187:drug effects; D014599:Uterus / Q000187:drug effects
D000020:Abortifacient Agents, Nonsteroidal; D000021:Abortifacient Agents, Steroidal; D011372:Progestins; D011453:Prostaglandins; D011980:Receptors, Progesterone; D016595:Misoprostol; D015735:Mifepristone; D013762:Tetrahydrofolate Dehydrogenase; D008727:Methotrexate